

CURRICULUM VITAE

Alessandra Larocca, MD, PhD

Department of Molecular Biotechnology and Health Sciences
Università degli Studi di Torino
Division of Hematology
Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino
via Genova 3, 10126 Torino
Tel (011) 6335878

Education and Training

High School Qualification Liceo Scientifico Statale G. Casiraghi	July 1995
Degree in Medicine University of Milano, Italy	October 22, 2001
MD license to practice and inclusion into the MD professional registry	July, 2002
Specialization School in Hematology Department of Hematology, San Gerardo Hospital, Monza University of Milano, Italy	November 16, 2005
PhD program in Pathology and Experimental Oncology, University of Torino Italy	2010-to October 2014

Professional and Research Experience

Internship, Department of Hematology, Ospedale San Gerardo, University of Milano, Italy	1999-2001
Residency and fellowship, Department of Hematology, Ospedale San Gerardo, University of Milano, Italy	November 2001-November 2005
Internship, Department of Hematology and Transplant Unit San Martino Hospital, Genova, Italy	November 2004-June 2005
Recipient of research fund from "Luce e Vita" foundation, Department of Hematology, Ospedale San Gerardo, University of Milano, Italy	2006
Recipient of research fund from "Rete onco-ematologica di Piemonte e Valle d'Aosta" foundation, Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Italy	2007-to 2013
Tenure track researcher - Hematology Department of Molecular Biotechnology and Health Sciences Division of Hematology	2013 to date

Educational Titles

- 2019-2020. Tenure track researcher at the University of Torino, Department of Molecular Biotechnology and Health Sciences, Degree Program in Medicine and Surgery (4th year). Integrated course title: *Clinics and Pathology of Hematology and Immunology* (with Prof. M. Boccadoro).
- 2017-2018. Tenure track researcher at the University of Torino, Department of Molecular Biotechnology and Health Sciences, Degree Program in Medical Biotechnology, Master Program (2nd year). Course title: *Biotechnological Therapies in Hematology* (II).
- 2014-2016. Tenure track researcher at the University of Torino, Department of Molecular Biotechnology and Health Sciences, Degree Program in Medical Biotechnology, Bachelor Program. Course title: *Medical Physiopathology* (optional class).

Relevant clinical research experience

Activities as hematology specialist, including diagnosis and treatment of hematologic patients, in particular those with lymph-proliferative and plasma cell disorders.

Clinical research skills, in particular in the field of multiple myeloma, working with the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and the European Myeloma Network (EMN).

Main research focuses on the diagnosis, clinical and experimental treatment of patients with multiple myeloma and associated disorders, particularly of elderly and frail patients. Dr. Larocca's also include the treatment of myeloma patients using new biological molecules and/or monoclonal antibodies.

Participation in various national and international clinical trials about lymph-proliferative and plasma cell disorders (currently sub-investigator in several clinical trials and local principal Investigator in 16 clinical trials).

More than 70 contributions on international peer-reviewed journals; H-Index 21.
(October 2019; source: Scopus – <https://www.scopus.com/>).

I authorize the processing of my personal data pursuant to art. 13 of Legislative Decree 30 June 2003, n. 196 "Code regarding the protection of personal data" and art. 13 of the GDPR (EU Regulation 2016/679).

Torino, October 24, 2019

Dr. Alessandra Larocca, MD, PhD

Publications – Full-text articles

1. Bringhen, S., D'Agostino, M., Paris, L., Ballanti, S., Pescosta, N., Spada, S., ... Larocca, A. (2019). Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial. *Haematologica*, haematol.2019.226407. <https://doi.org/10.3324/haematol.2019.226407>
2. Mateos, M.-V., Blacklock, H., Schjesvold, F., Oriol, A., Simpson, D., George, A., ... Yimer, H. (2019). Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. *The Lancet Haematology*, 6(9), e459–e469. [https://doi.org/10.1016/S2352-3026\(19\)30110-3](https://doi.org/10.1016/S2352-3026(19)30110-3)
3. Usmani, S. Z., Schjesvold, F., Oriol, A., Karlin, L., Cavo, M., Rifkin, R. M., ... Houck, W. (2019). Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naïve multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. *The Lancet Haematology*, 6(9), e448–e458. [https://doi.org/10.1016/S2352-3026\(19\)30109-7](https://doi.org/10.1016/S2352-3026(19)30109-7)
4. Bringhen, S., Mina, R., Petrucci, M. T., Gaidano, G., Ballanti, S., Musto, P., ... Larocca, A. (2019). Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. *Haematologica*, 104(8), 1640–1647. <https://doi.org/10.3324/haematol.2018.208272>
5. Saltarella, I., Morabito, F., Giuliani, N., Terragna, C., Omedè, P., Palumbo, A., ... Ria, R. (2019). Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. *Journal of Hematology & Oncology*, 12(1), 4. doi: 10.1186/s13045-018-0691-4
6. Bringhen, S., Milan, A., D'Agostino, M., Ferri, C., Wäsch, R., Gay, F., ... Engelhardt, M. (2019). Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial Hypertension. *Journal of Internal Medicine*, 286(1), joim.12882. doi: 10.1111/joim.12882
7. Zweegman, S., & Larocca, A. (2019). Frailty in multiple myeloma: the need for harmony to prevent doing harm. *The Lancet Haematology*, 6(3), e117–e118. doi: 10.1016/S2352-3026(19)30011-0
8. Gambella, M., Omedé, P., Spada, S., Muccio, V. E., Gilestro, M., Saraci, E., ... Oliva, S. (2019). Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis. *Cancer*, 125(5), 750–760. doi: 10.1002/cncr.31854

9. Richardson, P. G., Oriol, A., Beksac, M., Liberati, A. M., Galli, M., Schjesvold, F., ... trial investigators, O. (2019). Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. *The Lancet Oncology*, 20(6), 781–794. doi: 10.1016/S1470-2045(19)30152-4
10. Larocca, A., Mina, R., Offidani, M., Liberati, A. M., Ledda, A., Patriarca, F., ... Bringhen, S. (2019). First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials. *Haematologica*, [Epub ahead of print]. doi: 10.3324/haematol.2019.220657
11. Mateos, M.-V., Blacklock, H., Schjesvold, F., Oriol, A., Simpson, D., George, A., ... Yimer, H. (2019). Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. *The Lancet Haematology*. doi: 10.1016/S2352-3026(19)30110-3
12. Larocca, A., Dold, S. M., Zweegman, S., Terpos, E., Wäsch, R., D'Agostino, M., ... Engelhardt, M. (2018). Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN). *Leukemia*, 32(8), 1697–1712. doi: 10.1038/s41375-018-0142-9
13. Bringhen, S., Milan, A., Ferri, C., Waesch, R., Gay, F., Larocca, A., ... Hypertension, I. S. A. (2018). Cardiovascular adverse events in modern myeloma therapy - Incidence and risks. A review from the European Myeloma Network (EMN) and Italian Society of Arterial Hypertension (SIIA). *HAEMATOLOGICA*, 103(9), 1422–1432. doi: 10.3324/haematol.2018.191288
14. Caers, J., Garderet, L., Kortüm, K. M., O'Dwyer, M. E., van de Donk, N. W. C. J., Binder, M., ... Engelhardt, M. (2018). European Myeloma Network recommendations on tools for the diagnosis and monitoring of multiple myeloma: what to use and when. *Haematologica*, 103(11), 1772–1784. doi: 10.3324/haematol.2018.189159
15. Gay, F., & Larocca, A. (2018). Special problems in the management of elderly patients with multiple myeloma. *European Journal of Internal Medicine*, 58, 64–69. doi: 10.1016/j.ejim.2018.05.027
16. Larocca, A., D'Agostino, M., & Boccadoro, M. (2018). Gentle yet effective combination therapy with novel agents in elderly multiple myeloma patients. *British Journal of Haematology*, 182(2), 165–167. doi: 10.1111/bjh.15260
17. Bringhen, S., Offidani, M., Palmieri, S., Pisani, F., Rizzi, R., Spada, S., ... Larocca, A. (2018). Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. *Critical Reviews in Oncology/Hematology*, 130, 27–35. doi: 10.1016/j.critrevonc.2018.07.003
18. Salvini, M., Troia, R., Giudice, D., Pautasso, C., Boccadoro, M., & Larocca, A. (2018). Pharmacokinetic drug evaluation of ixazomib citrate for the treatment of multiple myeloma. *Expert Opinion on Drug Metabolism & Toxicology*, 14(1), 91–99. doi: 10.1080/17425255.2018.1417388

19. Musto, P., Anderson, K. C., Attal, M., Richardson, P. G., Badros, A., Hou, J., ... Palumbo, A. (2018). Erratum: Second primary malignancies in multiple myeloma: An overview and IMWG consensus [Annals of Oncology, 28, (2017) (228-245)] DOI: 10.1093/annonc/mdw606. *Annals of Oncology*, 29(4), 1074. doi: 10.1093/annonc/mdx160
20. Larocca, A., & Palumbo, A. (2018). Frail patients with newly diagnosed multiple myeloma. In *Neoplastic Diseases of the Blood*. doi: 10.1007/978-3-319-64263-5_27
21. D'Agostino, M., Salvini, M., Palumbo, A., Larocca, A., & Gay, F. (2017). Novel investigational drugs active as single agents in multiple myeloma. *Expert Opinion on Investigational Drugs*, 26(6), 699–711. doi: 10.1080/13543784.2017.1324571
22. Genadieva Stavric, S., Bonello, F., Bringhen, S., Boccadoro, M., & Larocca, A. (2017). How is patient care for multiple myeloma advancing? *Expert Review of Hematology*, 10(6), 551–561. doi: 10.1080/17474086.2017.1326814
23. Gentile, M., Magarotto, V., Offidani, M., Musto, P., Bringhen, S., Teresa Petrucci, M., ... Morabito, F. (2017). Lenalidomide and low-dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials. *American Journal of Hematology*, 92(3), 244–250. doi: 10.1002/ajh.24621
24. Musto, P., Anderson, K. C., Attal, M., Richardson, P. G., Badros, A., Hou, J., ... Grp, I. M. W. (2017). Second primary malignancies in multiple myeloma: an overview and IMWG consensus. *ANNALS OF ONCOLOGY*, 28(2), 228–245. doi: 10.1093/annonc/mdw606
25. Larocca, A., Mina, R., Gay, F., Bringhen, S., & Boccadoro, M. (2017). Emerging drugs and combinations to treat multiple myeloma. *Oncotarget*, 8(36), 60656–60672. doi: 10.18632/oncotarget.19269
26. Zweegman, S., Engelhardt, M., Larocca, A., & Hematology, E. H. A. S. W. G. A. &. (2017). Elderly patients with multiple myeloma: towards a frailty approach? *CURRENT OPINION IN ONCOLOGY*, 29(5), 315–321. doi: 10.1097/CCO.0000000000000395
27. Esmá, F., Salvini, M., Troia, R., Boccadoro, M., Larocca, A., & Pautasso, C. (2017). Melphalan hydrochloride for the treatment of multiple myeloma. *EXPERT OPINION ON PHARMACOTHERAPY*, 18(11), 1127–1136. doi: 10.1080/14656566.2017.1349102
28. Salvini, M., Bonello, F., Boccadoro, M., & Larocca, A. (2017). Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma. *EXPERT REVIEW OF ANTICANCER THERAPY*, 17(1), 75–87. doi: 10.1080/14737140.2017.1266264
29. Offidani, M., Corvatta, L., Bringhen, S., Gentili, S., Troia, R., Maracci, L., ... Boccadoro, M. (2017). Salvage therapy in first relapse: a retrospective study in a large patient population with multiple myeloma. *European Journal of Haematology*, 98(3), 289–295. doi: 10.1111/ejh.12834
30. Larocca, A., & Palumbo, A. (2016). Optimizing Treatment for Elderly Patients With Newly Diagnosed Multiple Myeloma: A Personalized Approach. *JOURNAL OF CLINICAL ONCOLOGY*, 34(30), 3600+. doi: 10.1200/JCO.2016.68.6113

31. Pawlyn, C., Gay, F., Larocca, A., Roy, V., & Ailawadhi, S. (2016). Nuances in the Management of Older People With Multiple Myeloma. *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*, *11*(3), 241–251. doi: 10.1007/s11899-016-0323-4
32. Larocca, A., Bringhen, S., Petrucci, M. T., Oliva, S., Falcone, A. P., Caravita, T., ... Palumbo, A. (2016). A phase 2 study of three low-dose intensity subcutaneous bortezomib regimens in elderly frail patients with untreated multiple myeloma. *Leukemia*, *30*(6), 1320–1326. doi: 10.1038/leu.2016.36
33. Fouquet, G., Gay, F., Boyle, E., Bringhen, S., Larocca, A., Facon, T., ... Palumbo, A. (2016). Treatment of newly diagnosed elderly multiple myeloma. In *Cancer Treatment and Research* (Vol. 169). doi: 10.1007/978-3-319-40320-5_8
34. Palumbo, A., Bringhen, S., Mateos, M.-V., Larocca, A., Facon, T., Kumar, S., ... Rajkumar, S. V. (2015). Geriatric assessment predicts survival and toxicities in elderly myeloma patients: An International Myeloma Working Group report. *Blood*, *125*(13), 2068–2074. doi: 10.1182/blood-2014-12-615187
35. Larocca, A., & Palumbo, A. (2015). How I treat fragile myeloma patients. *Blood*, *126*(19), 2179–2185. doi: 10.1182/blood-2015-05-612960
36. Palumbo, A., Gay, F., Cavallo, F., Di Raimondo, F., Larocca, A., Hardan, I., ... Boccadoro, M. (2015). Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. *Journal of Clinical Oncology*, *33*(30), 3459–3466. doi: 10.1200/JCO.2014.60.2466
37. Terpos, E., Kleber, M., Engelhardt, M., Zweegman, S., Gay, F., Kastiris, E., ... European Myeloma Network. (2015). European Myeloma Network guidelines for the management of multiple myeloma-related complications. *Haematologica*, *100*(10), 1254–1266. doi: 10.3324/haematol.2014.117176
38. Musto, P., Simeon, V., Grossi, A., Gay, F., Bringhen, S., Larocca, A., ... Boccadoro, M. (2015). Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: Results from a Gruppo Ital. *Stem Cell Research and Therapy*, *6*(1). doi: 10.1186/s13287-015-0033-1
39. Morabito, F., Bringhen, S., Larocca, A., Wijermans, P., Victoria Mateos, M., Gimsing, P., ... Offidani, M. (2014). Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case-matched study. *American Journal of Hematology*, *89*(4), 355–362. doi: 10.1002/ajh.23641
40. Mateos, M.-V., Bringhen, S., Richardson, P. G., Lahuerta, J. J., Larocca, A., Oriol, A., ... Palumbo, A. (2014). Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy. *Haematologica*, *99*(6), 1114–1122. doi: 10.3324/haematol.2013.099341
41. Palumbo, A., Bringhen, S., Kumar, S. K., Lupparelli, G., Usmani, S., Waage, A., ... McCarthy, P. L. (2014). Second primary malignancies with lenalidomide therapy for newly

- diagnosed myeloma: A meta-analysis of individual patient data. *The Lancet Oncology*, 15(3), 333–342. doi: 10.1016/S1470-2045(13)70609-0
42. Bringhen, S., Petrucci, M. T., Larocca, A., Conticello, C., Rossi, D., Magarotto, V., ... Palumbo, A. (2014). Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. *Blood*, 124(1), 63–69. doi: 10.1182/blood-2014-03-563759
 43. Engelhardt, M., Terpos, E., Kleber, M., Gay, F., Waesch, R., Morgan, G., ... Network, E. M. (2014). European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. *HAEMATOLOGICA*, 99(2), 232–242. doi: 10.3324/haematol.2013.099358
 44. Palumbo, A., Rajkumar, S. V., San Miguel, J. F., Larocca, A., Niesvizky, R., Morgan, G., ... Orłowski, R. Z. (2014). International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 32(6), 587–600. doi: 10.1200/JCO.2013.48.7934
 45. Palumbo, A., Bringhen, S., Larocca, A., Rossi, D., Di Raimondo, F., Magarotto, V., ... Cavo, M. (2014). Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, 32(7), 634–640. doi: 10.1200/JCO.2013.52.0023
 46. Rocci, A., Gambella, M., Aschero, S., Baldi, I., Trusolino, L., Cavallo, F., ... Palumbo, A. (2014). MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients. *BRITISH JOURNAL OF HAEMATOLOGY*, 164(6), 841–850. doi: 10.1111/bjh.12719
 47. Offidani, M., Corvatta, L., Caraffa, P., Leoni, P., Pautasso, C., Larocca, A., & Palumbo, A. (2014). Pomalidomide for the treatment of relapsed-refractory multiple myeloma: A review of biological and clinical data. *Expert Review of Anticancer Therapy*, 14(5), 499–510. doi: 10.1586/14737140.2014.906904
 48. Falco, P., Cavallo, F., Larocca, A., Rossi, D., Guglielmelli, T., Rocci, A., ... Palumbo, A. (2013). Lenalidomide-prednisone induction followed by lenalidomide-melphalan-prednisone consolidation and lenalidomide-prednisone maintenance in newly diagnosed elderly unfit myeloma patients. *Leukemia*, 27(3), 695–701. doi: 10.1038/leu.2012.271
 49. Larocca, A., Child, J. A., Cook, G., Jackson, G. H., Russell, N., Szubert, A., ... Morgan, G. J. (2013). The impact of response on bone-directed therapy in patients with multiple myeloma. *BLOOD*, 122(17), 2974–2977. doi: 10.1182/blood-2013-04-498139
 50. Bringhen, S., Mateos, M. V., Zweegman, S., Larocca, A., Falcone, A. P., Oriol, A., ... Palumbo, A. (2013). Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials. *Haematologica*, 98(6), 980–987. doi: 10.3324/haematol.2012.075051

51. Petrucci, M. T., Levi, A., Bringhen, S., Scotti, S., Gentilini, F., Russo, S., ... Palumbo, A. (2013). Bortezomib, melphalan, and prednisone in elderly patients with relapsed/refractory multiple myeloma: A multicenter, open label phase 1/2 study. *Cancer*, *119*(5), 971–977. doi: 10.1002/cncr.27820
52. Larocca, A., Montefusco, V., Bringhen, S., Rossi, D., Crippa, C., Mina, R., ... Palumbo, A. (2013). Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: A multicenter phase 1/2 open-label study. *Blood*, *122*(16), 2799–2806. doi: 10.1182/blood-2013-03-488676
53. Larocca, A., & Palumbo, A. (2013). Early combination studies in multiple myeloma. In *Advances in Biology and Therapy of Multiple Myeloma: Volume 2: Translational and Clinical Research*. doi: 10.1007/978-1-4614-5260-7_10
54. Bringhen, S., Larocca, A., & Rossi, D. (2012). Efficacy and safety of once-weekly bortezomib in multiple myeloma patients (Blood (2010) 116, 23 (4745-4753)). *Blood*, *120*(26), 5250. doi: 10.1182/blood-2012-11-466490
55. Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., ... Palumbo, A. (2012). Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. *Blood*, *119*(4), 933–939. doi: 10.1182/blood-2011-03-344333
56. Ferrero, S., Capello, D., Svaldi, M., Boi, M., Gatti, D., Drandi, D., ... Ladetto, M. (2012). Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*, *97*(6), 849–853. doi: 10.3324/haematol.2011.052852
57. Larocca, A., Cavallo, F., Mina, R., Boccadoro, M., & Palumbo, A. (2012). Current treatment strategies with lenalidomide in multiple myeloma and future perspectives. *FUTURE ONCOLOGY*, *8*(10), 1223–1238. doi: 10.2217/FON.12.124
58. Larocca, A., & Palumbo, A. (2012). Early combination studies in multiple myeloma. In *Advances in Biology and Therapy of Multiple Myeloma* (Vol. 2). doi: 10.1007/978-1-4614-5260-7_10
59. Gay, F., Larocca, A., Wijermans, P., Cavallo, F., Rossi, D., Schaafsma, R., ... Palumbo, A. (2011). Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. *Blood*, *117*(11), 3025–3031. doi: 10.1182/blood-2010-09-307645
60. Benevolo, G., Larocca, A., Gentile, M., Pregno, P., Gay, F., Botto, B., ... Palumbo, A. (2011). The Efficacy and Safety of Bortezomib and Dexamethasone as a Maintenance Therapy in Patients With Advanced Multiple Myeloma Who Are Responsive to Salvage Bortezomib-Containing Regimens. *CANCER*, *117*(9), 1884–1890. doi: 10.1002/cncr.25743
61. Larocca, A., & Palumbo, A. (2011). Evolving paradigms in the treatment of newly diagnosed multiple myeloma. *JNCCN Journal of the National Comprehensive Cancer Network*, *9*(10), 1186–1196. doi: 10.6004/jnccn.2011.0096
62. Palumbo, A., Larocca, A., Falco, P., Sanpaolo, G., Falcone, A. P., Federico, V., ... Boccadoro, M. (2010). Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for

- relapsed/refractory multiple myeloma. *Leukemia*, 24(5), 1037–1042. doi: 10.1038/leu.2010.58
63. Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., ... Boccadoro, M. (2010). Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. *Journal of Clinical Oncology*, 28(34), 5101–5109. doi: 10.1200/JCO.2010.29.8216
 64. Offidani, M., Leoni, P., Bringhen, S., Corvatta, L., Larocca, A., Gentili, S., ... Palumbo, A. (2010). Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: A case-match study. *Leukemia and Lymphoma*, 51(8), 1444–1449. doi: 10.3109/10428194.2010.486878
 65. Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., ... Palumbo, A. (2010). Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. *Blood*, 116(23), 4745–4753. doi: 10.1182/blood-2010-07-294983
 66. Palumbo, A., Larocca, A., Genuardi, M., Kotwica, K., Gay, F., Rossi, D., ... GIMEMA. (2010). Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*, 95(7), 1144–1149. doi: 10.3324/haematol.2009.047913
 67. Palumbo, A., Falco, P., Falcone, A., Benevolo, G., Canepa, L., Gay, F., ... G, I. M. M. N. (2009). Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Myeloma: Kinetics of Neutropenia and Thrombocytopenia and Time-to-Event Results. *CLINICAL LYMPHOMA & MYELOMA*, 9(2), 145–150. doi: 10.3816/CLM.2009.n.035
 68. Larocca, A., Cavallo, F., Magarotto, V., Rossi, D., Patriarca, F., Boccadoro, M., & Palumbo, A. (2008). Defibrotide: a review on clinical use and future development. *EXPERT OPINION ON BIOLOGICAL THERAPY*, 8(8), 1201–1212. doi: 10.1517/14712590802231853
 69. Palumbo, A., Magarotto, V., Larocca, A., Bringhen, S., Falco, P., Di Raimondo, F., ... Boccadoro, M. (2008). Treatment of newly diagnosed multiple myeloma. *Current Hematologic Malignancy Reports*, 3(2), 107–114. doi: 10.1007/s11899-008-0016-8
 70. Falco, P., Cavallo, F., Larocca, A., Liberati, A. M., Musto, P., Boccadoro, M., & Palumbo, A. (2008). Lenalidomide and its role in the management of multiple myeloma. *EXPERT REVIEW OF ANTICANCER THERAPY*, 8(6), 865–874. doi: 10.1586/14737140.8.6.865
 71. Larocca, A., Piaggio, G., Podestà, M., Pitto, A., Bruno, B., Di Grazia, C., ... Bacigalupo, A. (2006). A boost of CD34 + -selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. *Haematologica*, 91(7), 935–940. Retrieved from <https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745801062&partnerID=40&md5=a9ed605cf7f8497aa82cd204714efde3>
 72. Rossini, F., Terruzzi, E., Verga, L., Larocca, A., Marinoni, S., Miccolis, I., ... Pogliani, E. M. (2005). A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia. *Supportive Care in Cancer*, 13(6), 387–392. doi: 10.1007/s00520-004-0753-8

73. Pogliani, E. M., & Larocca, A. (2002). Anti-CD20 monoclonal antibody in autoimmune diseases. *Internal Medicine Clinical and Laboratory*, 10(1–3), 3–6. Retrieved from <https://www.scopus.com/inward/record.uri?eid=2-s2.0-0842263897&partnerID=40&md5=f78a98b00bfe584bd4a76bbfeebb739f>